SC
JBIO

Stempoint Capital’s Jade Biosciences JBIO Stock Holding History

Stempoint Capital’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.16M Buy
+154,034
New +$2.23M 0.41% 51

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Stempoint Capital's JBIO Position: Q1 2026 in Review

Stempoint Capital opened a new position in Jade Biosciences (JBIO) in Q1 2026: 154,034 shares worth $2.16M. The stake represents 0.41% of the portfolio and ranks #51 among its holdings.

120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Stempoint Capital held 154,034 shares of Jade Biosciences worth $2.16M as of Q1 2026.
  • Jade Biosciences was a new Stempoint Capital position in Q1 2026.
  • Jade Biosciences made up 0.41% of Stempoint Capital's portfolio in Q1 2026, its #51 holding.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.